CD19 and Alzheimer disease: The increase of the number of lymphocytes observed in TET-AD patients (Figure 1), prompted us to investigate potential difference between the two groups of patients in the percentage of lymphocyte subsets: T, (CD3+, CD4+, CD8+), B (CD19+) and natural killer (NK, CD56+).